2020
30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME
VADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-30-or.Peer-Reviewed Original ResearchInsulin-naïve patientsInsulin useBackground glucose-lowering therapyEMPA-REG OUTCOMEInsulin dose increasesInsulin-treated patientsGlucose-lowering therapyEmpagliflozin 10T2D durationInsulin doseT2D diagnosisInsulin needsPlaceboPatientsWeight gainKey covariatesDose increaseInsulinTreatment effectsNew initiationHypoglycemiaT2DTherapyYrDiagnosis927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4
PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4. Diabetes 2020, 69 DOI: 10.2337/db20-927-p.Peer-Reviewed Original ResearchNovo Nordisk A/SDohme Corp.Oral semaglutideMerck SharpGLP-1RAsSanofi-AventisNovartis AGRoche PharmaSGLT2 inhibitorsSubgroup analysisEli LillyGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDaily oral semaglutideTrial product estimandGastrointestinal adverse eventsLexicon PharmaceuticalsSubgroup of patientsJanssen Scientific AffairsType 2 diabetesBayer AGBoehringer Ingelheim PharmaceuticalsAdvisory PanelSubcutaneous liraglutideT2D duration
2018
Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort
RASOULI N, COHEN R, DEFRONZO R, INZUCCHI S, ISMAIL-BEIGI F, KAHN S, UTZSCHNEIDER K, LACHIN J, YOUNES N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort. Diabetes 2018, 67 DOI: 10.2337/db18-1822-p.Peer-Reviewed Original ResearchC-peptide responseBaseline phenotypic characteristicsDisposition indexInsulin sensitivityBoehringer Ingelheim PharmaceuticalsΒ-cell functionT2D durationJanssen PharmaceuticalsBristol-Myers Squibb CompanyNational Diabetes Education ProgramBoehringer Ingelheim GmbHBeta-cell responseType 2 diabetesΒ-cell responseDiabetes education programΒ-cell dysfunctionWaist circumferenceBlood InstituteKidney diseaseNational HeartAbbVie Inc.Grade cohortsCelgene CorporationDisease controlBaseline phenotype